Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Brock Reeve"'
Autor:
Deepak Bhere, Sung Hugh Choi, Pim van de Donk, David Hope, Kiki Gortzak, Amina Kunnummal, Jasneet Khalsa, Esther Revai Lechtich, Clemens Reinshagen, Victoria Leon, Nabil Nissar, Wenya Linda Bi, Cheng Feng, Hongbin Li, Yu Shrike Zhang, Steven H. Liang, Neil Vasdev, Walid Ibn Essayed, Pablo Valdes Quevedo, Alexandra Golby, Naima Banouni, Anna Palagina, Reza Abdi, Brian Fury, Stelios Smirnakis, Alarice Lowe, Brock Reeve, Arthur Hiller, E. Antonio Chiocca, Glenn Prestwich, Hiroaki Wakimoto, Gerhard Bauer, Khalid Shah
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-16 (2022)
Abstract Cellular therapies offer a promising therapeutic strategy for the highly malignant brain tumor, glioblastoma (GBM). However, their clinical translation is limited by the lack of effective target identification and stringent testing in pre-cl
Externí odkaz:
https://doaj.org/article/c3728edd112e43e6baeb95ff129c6000
Autor:
David Pettitt, Zeeshaan Arshad, Benjamin Davies, James Smith, Anna French, Doug Cole, Kim Bure, Sue Dopson, David DiGiusto, Jeff Karp, Brock Reeve, Richard Barker, Georg Holländer, David Brindley
Publikováno v:
Systematic Reviews, Vol 6, Iss 1, Pp 1-6 (2017)
Abstract Background Cellular-based therapies represent a platform technology within the rapidly expanding field of regenerative medicine and are distinct from conventional therapeutics—offering a unique approach to managing what were once considere
Externí odkaz:
https://doaj.org/article/debb75d532b747d7be8aea502500d5aa
Autor:
Benjamin M Davies, James Smith, Sarah Rikabi, Karolina Wartolowska, Mark Morrey, Anna French, Robert MacLaren, David Williams, Kim Bure, Rafael Pinedo-Villanueva, Anthony Mathur, Martin Birchall, Evan Snyder, Anthony Atala, Brock Reeve, David Brindley
Publikováno v:
Journal of Tissue Engineering, Vol 8 (2017)
Cellular therapies, such as stem cell–based treatments, have been widely researched and numerous products and treatments have been developed. Despite this, there has been relatively limited use of these technologies in the healthcare sector. This s
Externí odkaz:
https://doaj.org/article/49777decd9a84ce2b64bc843cf99eddd
Autor:
Benjamin M Davies, Sarah Rikabi, Anna French, Rafael Pinedo-Villanueva, Mark E Morrey, Karolina Wartolowska, Andrew Judge, Robert E MacLaren, Anthony Mathur, David J Williams, Ivan Wall, Martin Birchall, Brock Reeve, Anthony Atala, Richard W Barker, Zhanfeng Cui, Dominic Furniss, Kim Bure, Evan Y Snyder, Jeffrey M Karp, Andrew Price, Andrew Carr, David A Brindley
Publikováno v:
Journal of Tissue Engineering, Vol 5 (2014)
There has been a large increase in basic science activity in cell therapy and a growing portfolio of cell therapy trials. However, the number of industry products available for widespread clinical use does not match this magnitude of activity. We hyp
Externí odkaz:
https://doaj.org/article/16702e59821c4beaa187e0c04cb06840
Autor:
Brock Reeve
Publikováno v:
Cell and Gene Therapy Insights. :595-600
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dcf4f76fc72593bdb505ddba97c3d25a
https://doi.org/10.18609/cgti.2022.091
https://doi.org/10.18609/cgti.2022.091
Autor:
Deepak Bhere, Oren Levy, Nabeel Nissar, Erika M. J. Siren, Yuka Milton, Martina Heinelt, Mohanad Fallatah, Khalid Shah, Michael De Biasio, Abdulaziz Almalik, Brock Reeve, Jeffrey M. Karp, Ali H. Alhasan, Rui Kuai, Reza Abdi, Meshael Alturki
Publikováno v:
Science Advances
To realize the potential of MSCs, bioengineering is needed to boost potency and control heterogeneity.
More than 1050 clinical trials are registered at FDA.gov that explore multipotent mesenchymal stromal cells (MSCs) for nearly every clinical a
More than 1050 clinical trials are registered at FDA.gov that explore multipotent mesenchymal stromal cells (MSCs) for nearly every clinical a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::952dd1c97a2ff70ac47ccae7a7059a90
http://europepmc.org/articles/PMC7439491
http://europepmc.org/articles/PMC7439491
Publikováno v:
Stem Cells Translational Medicine
The 3Rs for a good education are “reading, 'riting, and 'rithmetic.” The basis for good health care solutions for the emergent field of cell therapy in the future will also involve 3Rs: regulation, reimbursement, and realization of value. The bus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f95b3ee87c002e274d77d78617f5f3b6
http://europepmc.org/articles/PMC5442742
http://europepmc.org/articles/PMC5442742
Autor:
Kelvin S, Ng, James A, Smith, Matthew P, McAteer, Benjamin E, Mead, Jamie, Ware, Felix O, Jackson, Alison, Carter, Lino, Ferreira, Kim, Bure, Jon A, Rowley, Brock, Reeve, David A, Brindley, Jeffrey M, Karp
Publikováno v:
Biotechnology and Bioengineering
Newly recognized as natural nanocarriers that deliver biological information between cells, extracellular vesicles (EVs), including exosomes and microvesicles, provide unprecedented therapeutic opportunities. Large‐scale and cost‐effective manufa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::faa2e4b3f3e76d74536bd1b0479d6a80
http://ora.ox.ac.uk/objects/uuid:
http://ora.ox.ac.uk/objects/uuid:
Autor:
Amit Chandra, Mahendra S. Rao, Hae-Won Kim, Doug Sipp, Glyn Stacey, Guillermo García-Cardeña, Joseph C. Wu, Alexander Meissner, Jonathan C. Knowles, Natalie Artzi, Joseph D. Gold, Andrew Carr, David Brindley, Ivan B. Wall, Christopher A. Bravery, David J. Williams, Peter R.T. Archibald, Richard W. Barker, James R. Smith, Kim Bure, Anna French, Jeanne F. Loring, Brock Reeve, Evan Y. Snyder, Jeffrey M. Karp, Steve Oh
Publikováno v:
Stem Cells Translational Medicine. 4:217-223
Summary There is a need for physical standards (reference materials) to ensure both reproducibility and consistency in the production of somatic cell types from human pluripotent stem cell (hPSC) sources. We have outlined the need for reference mater
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::679d39e9e846654a7919a40245c3a73e
https://doi.org/10.5966/sctm.2014-0233
https://doi.org/10.5966/sctm.2014-0233
Autor:
Andrew Carr, Brock Reeve, Laurence Daheron, Anna French, Hae-Won Kim, Kelvin S. Ng, Kim Bure, Peter J. Coffey, Richard J. Barker, David J. Williams, Mahendra Rao, Hannah Hurley, Jeffrey M. Karp, James A. Smith, David Brindley, Benjamin E. Mead, Ivan Wall, Marli Silva, Evan Y. Snyder, Justin J. Cooper-White
Publikováno v:
Cell Stem Cell. 16:13-17
Induced pluripotent stem cells (iPSCs) have the potential to transform drug discovery and healthcare in the 21(st) century. However, successful commercialization will require standardized manufacturing platforms. Here we highlight the need to define
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1909c9a4c73dba8691392e13ff4edd5
https://doi.org/10.1016/j.stem.2014.12.013
https://doi.org/10.1016/j.stem.2014.12.013